STOKE THERAPEUTICS INC's ticker is STOK and the CUSIP is 86150R107. A total of 108 filers reported holding STOKE THERAPEUTICS INC in Q4 2022. The put-call ratio across all filers is 0.29 and the average weighting 0.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $42 | -62.5% | 10,688 | +1.2% | 0.00% | – |
| Q2 2023 | $112 | -6.7% | 10,566 | -26.6% | 0.00% | – |
| Q1 2023 | $120 | -9.8% | 14,398 | 0.0% | 0.00% | – |
| Q4 2022 | $133 | -99.9% | 14,398 | +0.0% | 0.00% | – |
| Q3 2022 | $185,000 | -2.1% | 14,395 | +0.5% | 0.00% | – |
| Q2 2022 | $189,000 | -37.6% | 14,329 | -0.3% | 0.00% | – |
| Q1 2022 | $303,000 | -11.9% | 14,375 | +0.1% | 0.00% | – |
| Q4 2021 | $344,000 | -18.5% | 14,358 | -13.5% | 0.00% | – |
| Q3 2021 | $422,000 | -24.1% | 16,601 | +0.6% | 0.00% | -100.0% |
| Q2 2021 | $556,000 | +8.4% | 16,507 | +25.1% | 0.00% | 0.0% |
| Q1 2021 | $513,000 | -25.3% | 13,200 | +18.9% | 0.00% | 0.0% |
| Q4 2020 | $687,000 | +84.7% | 11,100 | 0.0% | 0.00% | – |
| Q3 2020 | $372,000 | +40.4% | 11,100 | 0.0% | 0.00% | – |
| Q2 2020 | $265,000 | +20.5% | 11,100 | +15.6% | 0.00% | – |
| Q1 2020 | $220,000 | -19.1% | 9,600 | 0.0% | 0.00% | – |
| Q4 2019 | $272,000 | +32.0% | 9,600 | 0.0% | 0.00% | – |
| Q3 2019 | $206,000 | – | 9,600 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ATP Life Science Ventures, L.P. | 16,786,713 | $562,187,000 | 75.80% |
| RTW INVESTMENTS, LP | 3,544,248 | $118,697,000 | 2.86% |
| Cormorant Asset Management, LP | 1,537,807 | $51,501,000 | 1.98% |
| Redmile Group, LLC | 2,549,506 | $85,383,000 | 1.57% |
| Birchview Capital, LP | 40,000 | $1,340,000 | 0.45% |
| HighVista Strategies LLC | 17,082 | $572,000 | 0.42% |
| Perceptive Advisors | 671,978 | $22,505,000 | 0.33% |
| GILDER GAGNON HOWE & CO LLC | 1,490,153 | $49,905,000 | 0.31% |
| Artal Group S.A. | 270,750 | $9,067,000 | 0.22% |
| VIRTUS ALTERNATIVE INVESTMENT ADVISERS, INC. | 323 | $11,000 | 0.20% |